Posted 28 January 2025
SVI welcomes Professor John Wentworth, the first to introduce at-home finger prick screening for type 1 diabetes, now widely used in Australia and being adopted in other countries.
John is an adult endocrinologist who aims to improve diabetes treatments and prevention strategies. He has joined SVI’s Immunology Lab as Senior Clinical Research Fellow.
His research focuses on screening to detect type 1 diabetes early and preserving beta cell function with disease-modifying immune therapies. John was the lead clinical investigator of the BANDIT trial that showed oral immunotherapy paired with baricitinib, preserves beta cell function.
The appointment further strengthens SVI’s type one diabetes research capabilities and solidifies the Institute’s position as a leader in the field.
Professor Tom Kay, Director of SVI and Head of the Immunology Lab says: “We are delighted to welcome John, a respected clinician researcher, and look forward to a continuation of our collaborative and impactful work.”
In addition to research and clinical work, John is the head of the Australasian T1D Immunotherapy Collaborative (ATIC), leads the Type1Screen national islet autoantibody screening program and is a co-investigator for the ENDIA birth-cohort study and the National Screening Pilot.
Learn more about ATIC